TCNP Encapsulated Red Cell Therapy for Pulmonary Fibrosis – AYX-101

Lung fibrosis affects alveoli structure

Revolutionary Cell Therapy Solution for Pulmonary Fibrosis Patients

TCNP encapsulated red cell therapy for pulmonary indications

  • Pulmonary fibrosis (PF) is a chronic condition wherein lung tissue is damaged and scarred with multiple etiologies (radiation, chemotherapy, genetics, drugs).
  • Diagnosis is accomplished using imaging tests (e.g., CT) and lung function tests (e.g., spirometry).
  • When a particular causal agent is not conclusive, it is considered idiopathic pulmonary fibrosis (IPF).
  • Nintedanib (Ofev) and pirfenidone (Esbriet) are FDA-approved drugs; however, there is a need for newer treatments with better effectiveness and tolerability.